Duphalac Dry

Quick links to important sections

Duphalac Dry

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duphalac Dry

Quick Facts

Property Description
Active ingredient Lactulose (INN)
Form Crystalline powder (for oral solution)
Pharmacological class Osmotic Laxative, Ammonia Detoxicant
Common general purpose Relief of chronic constipation
Origin Synthetic disaccharide

Defining Duphalac Dry: Composition and Pharmacological Class

Duphalac Dry is a pharmaceutical preparation that contains the active ingredient, Lactulose, which is an osmotic laxative. This medicine is distinctive for its dosage form, presented as a crystalline powder intended for oral administration after reconstitution. The Lactulose molecule is a synthetic disaccharide, manufactured from the sugars galactose and fructose. The use of agents in this class is based on their physical action in the bowel. Due to a secondary mechanism involving the modification of gut flora, it is also categorized as an Ammonia Detoxicant.

What is the General Therapeutic Purpose of Lactulose?

The general therapeutic purpose of this preparation is to provide management for constipation by promoting stool softening and facilitating regular bowel movements. The therapeutic effectiveness is directly related to the drug's osmotic properties. A common use involves supporting patients who require long-term, predictable relief from chronic constipation. The unique fermentation action of the Lactulose molecule in the large intestine forms the basis for its application in addressing conditions associated with elevated levels of ammonia in the blood, a crucial dual function of this compound.

Understanding the Non-Systemic Action

One defining characteristic of Duphalac Dry is its non-systemic action. The Lactulose molecule is notably resistant to human digestive enzymes, allowing it to pass through the upper gastrointestinal tract largely unchanged, which is why it is classified as a non-absorbable drug. This non-absorbable transit ensures that the drug's therapeutic effects are localized strictly to the colon. The unique dry powder form offers a point of differentiation from the more traditional viscous liquid formulations of Lactulose, providing an alternative preparation method without altering the fundamental therapeutic mechanism.

What side effects are possible with Duphalac Dry?

Possible side effects and safety information

The safety profile for the active ingredient, Lactulose, is organized by frequency and the body's organ systems, as defined in official regulatory documents. Most commonly reported adverse reactions involve the gastrointestinal system.

Adverse Reactions by Frequency (Regulatory Classification)

Frequency Reported Adverse Reactions (System-Organ Class)
Very Common (1/10) Diarrhea, Flatulence (Gastrointestinal Disorders)
Common (1/100 to < 1/10) Abdominal pain, Nausea, Vomiting (Gastrointestinal Disorders)
Not Known Hypersensitivity reactions, Rash, Pruritus (Skin and Immune System Disorders)

Flatulence is frequently noted as a transient effect that typically lessens after the first few days of treatment. Conversely, Diarrhea is a dose-dependent effect, classified as very common, and often indicates an unadjusted dosage.

Serious Adverse Reactions and Safety Constraints

A clinically significant concern documented in regulatory labeling is the potential for electrolyte imbalance (such as hypokalemia or hypernatremia), particularly when severe diarrhea persists due to unadjusted high doses or misuse over time. This reaction is classified under the Investigations System-Organ Class.

Safety constraints and contraindications listed in official documents include an absolute prohibition for use in patients with galactosemia or gastrointestinal obstruction (including the risk of perforation).

For older adults or debilitated patients receiving long-term treatment (over six months), regulatory documents advise periodic monitoring of serum electrolytes. The use of Lactulose in the pediatric population may also be subject to specialized guidance.

Overdose and Emergency Response

The official regulatory profile for Duphalac Dry (Lactulose) overdose is primarily defined by the consequences of an excessive dose leading to severe gastrointestinal distress. Documented overdose manifestations include severe diarrhea, intense abdominal pain, and abdominal cramps, reflecting an exaggerated osmotic effect. Excessive ingestion may also result in nausea and vomiting.


Severe Outcomes and Emergency Response

The primary severe risk documented in official labeling is the potential for extensive loss of fluids, which can rapidly lead to a serious electrolyte imbalance. The specific metabolic complications listed are hypokalemia (low serum potassium) and hypernatremia (high serum sodium).

When an excessive dose is suspected, the initial action mandated by regulators is the cessation of treatment or immediate dose reduction. Because of the potential for severe fluid and electrolyte loss, urgent medical attention is required when symptoms necessitate the correction of electrolyte disturbances. Management is limited to symptomatic treatment to address these fluid and metabolic deficits, as official regulatory documentation confirms that no specific antidote is known for Lactulose overdose. The presence of these severe complications defines the regulatory trigger for seeking help.

Therapeutic Uses of Duphalac Dry

What Duphalac Dry Treats: Main Uses and Benefits

This preparation is primarily used in the gastroenterology domain to manage chronic functional constipation, a condition characterized by symptoms related to physical discomfort from infrequent and difficult bowel movements. This medication is used for the management of constipation and to assist with stool softening. The primary therapeutic benefit is promoting stool softening, which helps make episodes of bowel movement easier to tolerate and contributes to improved comfort during periods of heightened symptoms.


An important secondary application is its use in the hepatology domain for addressing complications like Hepatic Encephalopathy (HE), which involves symptoms related to systemic imbalance. This is relevant for managing symptom clusters like confusion and disorientation linked to elevated blood ammonia. The primary symptom domains this preparation is used for managing are chronic constipation and the symptomatic manifestations of portal-systemic encephalopathy. This intervention provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases in patients with liver disease.

“This medicine is commonly used across conditions where long-term, supportive symptom management is appropriate.”

The medication offers symptomatic relief that is highly localized to the colon. This non-systemic action can contribute to easing the overall symptom load while providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Symptomatic Support

Symptom Category Therapeutic Focus Primary Benefit
Difficult Bowel Movement Chronic irregularity Contributes to supporting regularity
Hard Stool Consistency Physical discomfort Promotes stool softening
Systemic Imbalance Elevated toxins Assists with systemic imbalance

Regulatory References

  1. NIH MedlinePlus overview of Lactulose

Eligibility and Restrictions for Use

Who Can and Cannot Use Duphalac Dry?

The population eligibility for Duphalac Dry (Lactulose) is defined by official regulatory bodies, primarily based on the presence of specific comorbidities and patient age.

Contraindications (Must Not Use)

Lactulose is absolutely contraindicated for patients diagnosed with galactosaemia or those requiring a galactose-free diet. Use is also prohibited in patients with confirmed or suspected gastrointestinal obstruction, digestive perforation or risk thereof, and acute inflammatory bowel diseases such as Crohn's disease or ulcerative colitis. Patients with rare hereditary problems like glucose-galactose malabsorption must also avoid this medicine.


Eligibility by Patient Group

Patient Group Constipation Eligibility Hepatic Encephalopathy (HE) Status
Adults & Adolescents Approved (Standard Use) Approved (Standard Use)
Children & Infants Exceptional, under medical supervision Safety and efficacy are not established
Older Adults Approved (No special dosage needed) Approved (No special dosage needed)

Special Conditions

Due to the negligible systemic absorption of lactulose, the official label states that the medicine can be used during pregnancy and breastfeeding. No specific dosage adjustments are required for patients with renal or hepatic insufficiency. However, use in patients with Diabetes Mellitus requires caution due to the presence of residual sugars in the formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Duphalac Dry (Lactulose) focuses on pharmacodynamic interactions that arise from its non-systemic action in the colon.

Documented Pharmacodynamic Interactions

Interacting Product Category Official Interaction Outcome
Non-absorbable antacids Co-administration may inhibit the desired drop in colonic pH, potentially interfering with Lactulose's effects.
Potassium-losing agents (e.g., Diuretics, Corticosteroids, Amphotericin B) Lactulose-induced diarrhea may increase the loss of potassium caused by these agents, which can lead to or worsen hypokalemia (low potassium levels).

Secondary Exposure Modification

Due to the documented risk of hypokalemia, there is an indirect interaction with Cardiac Glycosides (e.g., Digoxin). The resulting low potassium levels may increase the effect and potential toxicity of these glycosides. No systemic pharmacokinetic interactions, such as those involving CYP enzymes, are documented, consistent with Lactulose’s minimal absorption.

Population-Specific Caution

Regulatory documents advise caution for co-administration with potassium-losing agents in patients prone to electrolyte disorders, including those with pre-existing renal impairment or hepatic impairment. No mandatory administration timing rules are specified in the official prescribing information.

Mechanism of Action

Microbial Fermentation and Colonic pH Modulation

The drug acts initially as a targeted substrate for colonic bacteria ( gut microbiota), which break down the non-absorbed disaccharide through fermentation. This process generates short-chain fatty acids ( SCFA), which fundamentally lowers the pH of the intestinal contents. This chemical change is essential for the subsequent physiological cascade.


Osmotic Activity and Peristalsis Stimulation

The SCFA and the unabsorbed drug create a powerful osmotic gradient within the colon, drawing water into the lumen. This increase in fluid volume softens the contents and physically distends the bowel wall, providing the necessary stimulus to promote peristalsis.


Molecular Ion Trapping and Nitrogen Management

The reduction in local pH facilitates the chemical process of ion trapping, converting diffusible waste products, specifically ammonia ( NH3), into the non-absorbable ammonium ion ( NH4^+). This mechanism restricts the absorption of these nitrogenous compounds into the systemic circulation, leading to a reduction in the overall systemic concentration of unabsorbed nitrogenous compounds.

Dosage and Administration Information

The established protocols for using Duphalac Dry (Lactulose Crystalline Powder) include specific administration routes, dosage regimens for different indications, and required preparation steps. The usage protocol is goal-directed, particularly in advanced conditions.


Administration Scope

Instruction Category Guideline
Route of administration Primarily Oral administration following reconstitution. Rectal administration (retention enema) is utilized for acute management of Hepatic Encephalopathy (HE).
Dosing schedule Chronic Constipation: Starting dose ranges from 10 g to 30 g daily; maintenance is typically 10 g to 20 g daily. Hepatic Encephalopathy (HE): Starting dose is 20 g to 35 g taken three to four times daily. The maintenance dose is titrated to achieve 2 to 3 soft stools per day.
Timing in relation to meals (if applicable) May be administered with or without food. Dosing is often suggested to be taken once daily at breakfast.
Preparation requirements (if applicable) The powder packet contents must be fully dissolved in at least 4 ounces (half a glass) of water or another suitable fluid, such as juice or milk.
Age-group administration rules Use in children under 14 years is classified as exceptional and requires close medical supervision. No routine dosage adjustments are specified for older adults.
Missed-dose rules If a dose is missed, it is skipped, and the subsequent dose should be taken at the usual time; compensation with a double dose is prohibited.
Special procedural conditions The reconstituted dose must be swallowed quickly. Patients receiving long-term treatment (over six months) should undergo periodic monitoring of serum electrolytes.

Connection to the overall use protocol

Standard instructions mandate that the crystalline powder be dissolved before oral or rectal administration, establishing a required reconstitution step. Dosing is structured based on the specific indication, requiring a high-frequency, goal-directed regimen for Hepatic Encephalopathy that is distinct from the lower, once-daily or divided pattern for chronic constipation. This procedural structure ensures the medicine is used consistently with label-based guidelines.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Duphalac Dry (Lactulose)

This section provides a descriptive overview of the types of clinical research and studies that have been conducted on Lactulose, the active ingredient in Duphalac Dry. The findings described reflect patterns observed in the studies and do not offer individual predictions or clinical recommendations. Study results reflect the specific conditions under which they were conducted.


️ Evidence for Use in Chronic Functional Constipation

This section will summarize the structure of Randomized Controlled Trials (RCTs) and meta-analyses that examined Lactulose in the context of chronic constipation. This body of research was studied for its use in patients experiencing conditions characterized by fluctuating or episodic manifestations and outcomes related to physical discomfort.

What Researchers Studied

Studies monitored outcomes related to physical discomfort, such as changes in weekly bowel movement frequency and assessment of stool consistency (using standardized scales). Research examined the effects of Lactulose in adult populations, including studies using comparative study designs.

What The Studies Reported

Findings describe patterns observed in the studies related to changes in bowel habits and consistency during the short-term follow-up periods. Studies report how symptoms evolved in the observed populations, noting changes measured during the study period in both stool frequency and patient-reported measures of defecation experiences. This research contributes to the broader evidence landscape, exploring short-term changes.


Evidence for Use in Hepatic Encephalopathy (HE)

This part will detail the research base, including systematic reviews and controlled trials, which evaluated the use of Lactulose for both the acute treatment and prevention of recurrence of Hepatic Encephalopathy (HE), a condition involving periods of heightened symptoms and systemic or functional imbalance.

What Researchers Studied

Research examined outcomes related to systemic or functional imbalance in adults with liver cirrhosis. Studies monitored measures of cognitive function and neuropsychological performance. They also tracked the recurrence rates for patients on a long-term regimen.

What The Studies Reported

In the acute setting, studies reported how symptoms evolved in the observed populations, noting patterns of change in HE symptoms and shifts in measured cognitive test scores. For studies examining prevention of recurrence (secondary prevention), research describes observed recurrence rates during the study periods. Comparative trials sometimes yielded mixed findings or described different observed outcomes for specific biomarker levels.


⏳ Long-Term Research and Follow-up Durations

The follow-up durations used in the clinical trials vary depending on the indication being studied. For acute constipation relief, the research is predominantly focused on short-term evaluations, with many trials concluding their primary assessment within four weeks or less. This research explores short-term symptom changes.

For the prevention of recurrence of Hepatic Encephalopathy, studies monitored patients over extended durations, with follow-up periods commonly tracking outcomes for six months or longer. While this information relates to recurrence patterns, the data for continuous, indefinite long-term effects are not fully established and are still emerging for general use.


Evidence in Specific Patient Populations

This topic describes the research that has specifically evaluated Lactulose in defined groups. Studies have explored its use in various adult populations, including an examination of its application in older adults with constipation. Research has also been conducted on patients with certain co-morbid conditions, such as those with constipation linked to diabetes.

Researchers note that the results apply only to the populations studied. Data for certain groups, such as pediatric or adolescent populations, remain limited in the synthesized evidence base.


Evidence Gaps and Areas of Scientific Uncertainty

This final section synthesizes the main key limitations that scientists and regulatory bodies have noted within the current body of research. While the evidence base contributes to understanding symptom patterns, it is characterized by areas of scientific uncertainty.

One noted limitation is the significant heterogeneity across trials in how key outcomes were defined and measured. This variability can complicate the comparison of findings across different studies. Additionally, comparative evidence is lacking for certain patient subsets, and subgroup findings are uncertain due to sample sizes being modest in specialized trials. There is limited information for long-term outcomes that track effects beyond the specific follow-up durations observed in the trials. The evidence highlights what is known—and what is still uncertain—about the observed research patterns.

Key Studies & References

  1. Lactulose Monograph (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Duphalac Dry (FAQ)


Q: Is Duphalac Dry the same thing as the liquid Duphalac?

Duphalac Dry is the crystalline powder version of the medicine, which is intended to be dissolved in a liquid before administration. The standard Duphalac is a pre-mixed, viscous liquid oral solution (or syrup). According to official product information, both dosage forms contain the same active medicinal ingredient, lactulose.

Q: How quickly should I expect Duphalac Dry to start working?

Regulatory documents state that since the action of the medicine is localized in the colon, it may take time for the therapeutic effect to become noticeable. The onset of effect is described in regulatory documents as occurring within 24 to 48 hours for the intended laxative effect or a normal bowel movement to occur.

Q: Does Duphalac Dry help with bloating or gas?

Bloating and flatulence (gas) are not listed as intended therapeutic effects in official documentation. In fact, regulatory documents classify flatulence as a very common side effect, particularly when treatment begins.

Q: Do I need a prescription to get Duphalac Dry?

The access status for Duphalac Dry is determined by local regulatory schedules. In some regions, the medicine may be available for the treatment of constipation without a prescription. However, access and requirements can vary significantly by country or region.

Q: Are there any known issues with taking Duphalac Dry and antibiotics at the same time?

Official documents specifically list interactions with non-absorbable antacids and potassium-losing agents. Specific classes of antibiotics are not consistently highlighted as a direct interaction. Official guidance suggests that a healthcare provider should be informed of all co-administered medicines, including antibiotics.

Q: Does Duphalac Dry contain sugar or lactose?

The active ingredient is lactulose, which is a synthetic sugar derived from galactose and fructose. According to regulatory warnings, the final product contains small residual amounts of other sugars, including lactose and trace amounts of galactose or epilactose.

Q: Does Duphalac Dry have an effect on kidney function?

Official product information notes that the drug is minimally absorbed systemically, and the small amount that is absorbed is promptly excreted. For patients with existing renal insufficiency (kidney impairment), regulatory documents do not specify any required dosage adjustments.

Q: Can Duphalac Dry be used for conditions other than its main approved uses?

Duphalac Dry is specifically indicated and approved for use in the treatment of chronic constipation and portal systemic encephalopathy (PSE). Official labeling does not support or approve the use of the medicine for any other conditions.

Q: Is Duphalac Dry considered a safe option for managing occasional issues?

Official product labeling states that the medicine is indicated for chronic constipation. Official guidance for laxatives generally notes that prolonged use is undesirable, and individuals with persistent symptoms are advised to seek guidance from a healthcare professional.

Q: Are there known interactions between Duphalac Dry and heart medications?

Regulatory documents identify an interaction risk involving cardiac glycosides, a class of heart medication. This is an indirect interaction where severe, high-dose use of lactulose can cause hypokalemia (low potassium), which in turn may increase the effect and toxicity of these glycosides.

Q: What is the typical time frame for the full effect to be achieved?

While the initial laxative effect may begin within 24–48 hours, the full therapeutic benefit may require two to three days to become fully established. For the treatment of Hepatic Encephalopathy, the dose is often adjusted until a specific goal of 2 to 3 soft stools per day is reached.

Q: Can Duphalac Dry affect blood pressure?

Blood pressure changes are not listed as a directly observed side effect in official adverse reaction tables. However, regulatory documents warn that high doses can lead to electrolyte imbalance from severe diarrhea, which can have an indirect effect on the body's overall fluid and cardiovascular balance.

Q: What is the main difference in how Duphalac Dry and bisacodyl work?

Official product information states that Duphalac Dry's mode of action is based on osmotic activity, where it draws water into the bowel. This method is noted in regulatory documents as being different from that of conventional laxatives, such as the stimulant class to which bisacodyl belongs.

Q: Does Duphalac Dry come in different package sizes?

Official product presentation information confirms that the Duphalac Dry powder sachets are distributed in different package sizes. Examples include packs of 10 or 30 sachets, each containing the standard amount of the active ingredient.

Q: Is Duphalac Dry recommended for individuals with kidney disease?

Official documents note that no special dosage adjustment is required for patients with renal insufficiency (kidney disease). This is due to its non-systemic action, which results in minimal absorption into the bloodstream.

Q: Can Duphalac Dry make certain medications less effective?

Regulatory documents note a potential for interference with certain other medications. Specifically, the drop in colonic pH caused by Duphalac Dry may reduce the effectiveness of medicines that rely on a specific pH for their release in the colon.

Q: What is the meaning of 'Dry' in the product name?

The term 'Dry' refers to the specific crystalline powder dosage form of the medicine. This differentiates it from the traditional viscous liquid solution of lactulose.

Q: Are there any reported interactions with herbal supplements?

Specific interactions involving herbal supplements are not consistently detailed across primary regulatory documents. However, official guidance indicates that healthcare providers should be informed about all co-administered products, including herbal remedies and supplements.

Q: Does Duphalac Dry help improve overall gut health?

Lactulose acts as a non-absorbed substrate for certain colonic bacteria in the large intestine. Studies and official information indicate that this process is associated with the proliferation of specific bacteria, which leads to the description of the substance as a prebiotic.

Q: Can I take Duphalac Dry if I have a fructose intolerance?

Since the medicine is manufactured from certain sugars, it may contain small residual amounts of lactose and fructose. Official warnings state that individuals with intolerances to certain sugars, including lactose intolerance, may need to consult a healthcare professional before use.

Q: Is Duphalac Dry generally considered non-habit forming?

Regulatory guidance and reviews indicate there is no evidence that lactulose leads to habit-forming behavior or physical dependence. However, prolonged or continuous use of any laxative is generally considered undesirable, and use duration is a clinical matter that requires guidance from a healthcare professional.

Q: Can Duphalac Dry be taken long-term?

Long-term use is permitted for certain indications, such as the prevention of Hepatic Encephalopathy. Official documentation states that for long-term treatment exceeding six months, especially in older or debilitated patients, periodic monitoring of serum electrolytes (blood minerals) is a required procedure.

How should Duphalac Dry be stored and disposed of?

Storage and Disposal Requirements for Duphalac Dry

The storage and disposal of Duphalac Dry (Lactulose crystalline powder) must adhere strictly to the conditions specified in regulatory labeling to maintain stability and ensure safety.


Storage Conditions

  • Temperature: Store the medicine at or below 25, C.
  • Child Safety: Keep the product out of the sight and reach of children at all times.
  • Shelf-Life: Do not use the medicine after the expiry date printed on the sachet and the carton.

Disposal Instructions

  • Prohibited Disposal: Do not dispose of unused medicine in drains or sewerage systems (i.e., wastewater).
  • Required Procedure: Unused or expired Duphalac Dry must be returned to a pharmacist for proper and safe handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Duphalac Dry found in:

A-Z Index: